Copper-67-Labeled Bombesin Peptide for Targeted Radionuclide Therapy of Prostate Cancer
The gastrin-releasing peptide receptor (GRPR) is a promising molecular target for imaging and therapy of prostate cancer using bombesin peptides that bind to the receptor with high affinity. Targeted copper theranostics (TCTs) using copper radionuclides, <sup>64</sup>Cu for imaging and &...
Main Authors: | Truc T. Huynh, Ellen M. van Dam, Sreeja Sreekumar, Cedric Mpoy, Benjamin J. Blyth, Fenella Muntz, Matthew J. Harris, Buck E. Rogers |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-06-01
|
Series: | Pharmaceuticals |
Subjects: | |
Online Access: | https://www.mdpi.com/1424-8247/15/6/728 |
Similar Items
-
Radiolabeled Bombesin Analogs
by: Rosalba Mansi, et al.
Published: (2021-11-01) -
Targeting the Gastrin-Releasing Peptide Receptor (GRP-R) in Cancer Therapy: Development of Bombesin-Based Peptide–Drug Conjugates
by: Jacopo Gomena, et al.
Published: (2023-02-01) -
Preclinical Evaluation of the Copper-64 Labeled GRPR-Antagonist RM26 in Comparison with the Cobalt-55 Labeled Counterpart for PET-Imaging of Prostate Cancer
by: Christina Baun, et al.
Published: (2020-12-01) -
Towards Cancer Nanoradiopharmaceuticals—Radioisotope Nanocarrier System for Prostate Cancer Theranostics Based on Radiation-Synthesized Polymer Nanogels
by: Beata Paulina Rurarz, et al.
Published: (2023-11-01) -
Bombesins: A New Frontier in Hybrid Compound Development
by: Pawel Serafin, et al.
Published: (2023-11-01)